Recent progress and considerations for AAV gene therapies targeting the central nervous system by Lykken, Erik A. et al.
REVIEW Open Access
Recent progress and considerations for
AAV gene therapies targeting the central
nervous system
Erik Allen Lykken1, Charles Shyng2, Reginald James Edwards2, Alejandra Rozenberg2 and Steven James Gray1*
Abstract
Background: Neurodevelopmental disorders, as a class of diseases, have been particularly difficult to treat even
when the underlying cause(s), such as genetic alterations, are understood. What treatments do exist are generally
not curative and instead seek to improve quality of life for affected individuals. The advent of gene therapy via
gene replacement offers the potential for transformative therapies to slow or even stop disease progression for
current patients and perhaps minimize or prevent the appearance of symptoms in future patients.
Main body: This review focuses on adeno-associated virus (AAV) gene therapies for diseases of the central nervous
system. An overview of advances in AAV vector design for therapy is provided, along with a description of current
strategies to develop AAV vectors with tailored tropism. Next, progress towards treatment of neurodegenerative diseases
is presented at both the pre-clinical and clinical stages, focusing on a few select diseases to highlight broad categories of
therapeutic parameters. Special considerations for more challenging cases are then discussed in addition to
the immunological aspects of gene therapy.
Conclusion: With the promising clinical trial results that have been observed for the latest AAV gene therapies
and continued pre-clinical successes, the question is no longer whether a therapy can be developed for
certain neurodevelopmental disorders, but rather, how quickly.
Keywords: Central nervous system, Adeno-associated virus, AAV9, Gene therapy, Clinical trial, Neutralizing antibody,
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Background
The need for long-lasting and transformative therapies for
neurodevelopmental disorders cannot be understated.
Traditional drug development is made particularly diffi-
cult for these disorders due to the blood-brain-barrier
(BBB) and off-target effects of drugs affecting neuronal
function. Central nervous system (CNS)-directed gene
therapy via gene replacement represents a powerful mo-
dality to achieve long-term correction of disorders follow-
ing a single treatment. Multiple vectors exist that can be
used for gene therapy, including integrating lentiviral vec-
tors and non-integrating adeno-associated virus (AAV)
vectors [1]. While lentiviral vectors offer stable transduc-
tion and roughly double the packaging capacity of AAV, in
the context of CNS-directed gene therapy, lentiviral vec-
tors have been more amenable to ex vivo treatment
approaches and thus far not as amenable as AAV for in
vivo gene transfer to widely target the CNS [2, 3]. Even
though other viral vectors have shown promise in certain
CNS gene therapy applications, this review will focus spe-
cifically on the progression towards and beyond the
current generation of CNS-directed AAV gene therapeutic
strategies. Information on basic AAV biology and vector
properties is reviewed elsewhere [1, 2]. Pre-clinical and
clinical progress towards the treatment of various neuro-
developmental disorders will be covered to highlight the
various challenges and potential therapeutic modalities
encountered with AAV gene therapy. Finally, some special
considerations for AAV-mediated gene therapy, including
potential immune responses, will be discussed.* Correspondence: steven.gray@utsouthwestern.edu
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Main text
The evolution of CNS-directed AAV gene therapy
Treatment of neurodevelopmental disorders using AAV vec-
tors represents a tremendous opportunity in the field of gene
therapy, though using a modified virus to target the CNS is
not without its challenges. The ideal CNS-directed gene
therapy will utilize minimally invasive delivery while targeting
the appropriate cell type(s) in target tissue(s) to achieve life-
long treatment following a single, low dose. The complexity
of the CNS, however, poses many obstacles to the ideal AAV
gene therapy, including the BBB, invasiveness of delivery,
and adequate viral spread from the delivery site [4–8]. Just as
for many traditional drugs, the BBB immediately prevents
the majority of minimally invasive, peripherally delivered (i.e.,
intravenous) AAV gene therapies from reaching the CNS.
However, the BBB is technically straightforward to bypass by
delivering therapy directly to the CNS. A number of pre-
clinical studies have demonstrated successful circumvention
of the BBB with intracranial gene therapy using intrapar-
enchymal injection [9, 10]. However, this method is highly
invasive and, upon translation to higher order mammals, the
distribution of AAV particles within the brain is restricted
[11, 12]. Overall, intracranial delivery translates to a lower
probability of efficacy in larger mammals.
Early CNS AAV studies utilized naturally occurring first
(AAV2) and second (AAV5 or AAV8) generation vectors
[9, 13–15]. In the last decade, a third-generation vector,
AAV9, was determined to have a wide distribution in the
brain and spinal cord, targeting both neurons and astro-
cytes [10, 16]. AAV9, unlike other naturally occurring se-
rotypes, readily crosses the BBB following intravenous
injection, thus permitting a minimally invasive treatment
modality [16–18]. Further, when injected intracranially or
intrathecally, no other AAV serotype has surpassed the
distribution of AAV9 [10, 17], permitting overall lower
dosing. It has been suggested that AAV9 achieves such
wide distribution due at least partially to an ability to
undergo axonal transport [10]. AAV9 was additionally ex-
citing because the tropism observed in rodent research
models has translated effectively to non-human primates.
AAV9 has thus become the gold standard for AAV-
mediated gene therapy of the CNS. AAV9 does have limi-
tations in its overall efficiency, however, and there remain
questions about whether its cellular tropism (neurons ver-
sus glia) translates unaltered between rodents and pri-
mates [19]. These questions, along with a relatively high
rate of naturally occurring humoral immunity to AAV9 in
the general population (~ 47%) [20], have prompted the
development of new and hopefully superior AAV capsids.
Current strategies for the development of
next-generation AAV vectors
Like other viruses, AAV tropism is determined by the spe-
cific interaction between distinct viral capsid proteins and
their cognate cellular receptors (Table 1). Thus, rational
design of enhanced AAV capsids requires an understand-
ing of the structural elements in both the capsid and re-
ceptor that will permit viral recognition and adhesion.
Attempts to use rational design to alter the nature of
capsid-receptor binding for gene therapy optimization
began in 1999 with a study focused on re-directing AAV2
tropism [21, 22]. This foundational study yielded an AAV2
capsid in which short peptides were inserted into the cap-
sid to disrupt binding to its normal cognate receptor, hep-
arin sulfate proteoglycan, and instead retargeted AAV2
variants to other receptors. Since this study, the structures
of many naturally occurring AAV capsids have been solved
and their cognate receptors identified [23–42]. With both
capsid and receptor structures known, structure-function
studies can identify critical binding footprints that mediate
tropism, and then capsids can be engineered with the ap-
propriate binding footprint to achieve the desired viral
tropism. An example of such an effort is the development
of the AAV2i8 capsid [43]. In these studies, the liver-
tropic AAV2 capsid binding footprint was swapped for
those of the muscle-tropic AAV8, resulting in a novel
liver-de-targeted and muscle-targeting capsid. Recent
work has further shown that even minor alterations to
binding footprints can drastically alter AAV tropism
[42, 44, 45]. Rational design therefore offers a powerful
tool to manipulate AAV tropism when building upon
known binding footprints and receptors. However, the
time and resources needed to elucidate capsid structure
and receptors for each novel capsid currently limits the
impact of rational design approaches and largely con-
fines rational design efforts to a limited, albeit growing,
structural toolbox.
In contrast to rational design, a directed evolution ap-
proach does not require any knowledge of capsid structure
or receptor identity. Directed evolution of an AAV capsid
starts with the utilization of random mutagenesis, capsid
shuffling, and/or random peptide insertions, and follows
with a selective pressure to isolate variants with desired
properties [7, 46–52]. Random mutagenesis of the capsid
DNA, typically by error-prone PCR, introduces amino
acid changes to generate a diverse capsid library. DNA
shuffling uses random digestion and ligation of a pool of
AAV capsid sequences, which, when followed by directed
evolution, permits for the potential convergence of unique
molecular footprints in one capsid [53–56]. For example,
seizure clone 83 is an amalgamation of five AAV serotypes
that can cross a seizure-compromised blood-brain-barrier
[56]. Relevant capsids are then recovered from the target
cell(s) or tissue(s), and then capsids undergo iterative
rounds of selection and recovery until a unique population
of AAV capsids becomes prominent. Directed evolution
has been applied both in vitro and in vivo to generate cap-
sids targeting a variety of different cell types and tissues.
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Directed evolution thus allows for the discovery of highly
specific AAV capsids, relying only on unbiased mutagen-
esis, selective pressure, and recovery methods. However,
from a research standpoint, the power of directed evolu-
tion is simultaneously its greatest weakness—a complete
lack of understanding of what sequences and structures
are critical for a given tropism.
Moving forward, future research studies could feasibly
combine rational design and directed evolution method-
ologies [8, 57]. Indeed, one such study generated a novel
AAV2 specific for brain endothelial cells of diseased, but
not healthy, animals [58]. Phage display technology was
then used to identify unique peptide sequences directed to
brain endothelia following intravenous injection, and the
peptide was then grafted onto the surface loop region of
AAV2. Thus, combining rational design and directed evo-
lution methods can potentially open many avenues for the
development of clinically relevant capsids by permitting
altered tropism to a desired cell or tissue.
Pre-clinical and clinical progress
Having a toolbox of vectors with altered tropism is an im-
portant step, but to develop an effective therapeutic ap-
proach, the cellular and molecular mechanisms driving a
disease must be well understood. Whether a disease results
from loss of non-cell-autonomous versus cell-autonomous
factors, necessary treatment modality, and required expres-
sion levels are all critical aspects of gene therapy develop-
ment and strategy. For example, a loss-of-function defect
in a single non-cell-autonomous factor greatly simplifies
the development of a successful gene therapy; in this sce-
nario, one need only to introduce a gene product to cells
that can secrete that protein, thereby making it available to
neighboring cells, which are then able to take up and use
the secreted protein. Mucopolysaccharidosis type IIIA
(MPS3A, OMIM # 252900) results from the loss of the
non-cell-autonomous enzyme heparan N-sulfatase and the
accumulation of glycosaminoglycan (GAG). Intravenous
administration of AAV9 expressing heparan N-sulfatase in
the MPS3A mouse model achieves whole body correction
of GAG accumulation and significantly prolongs lifespan
[59, 60]. However, the extent of therapeutic benefit critic-
ally depends on age at which an animal is treated; mice
treated at 3 months of age experienced phenotypic rescue
and normalized lifespans, whereas mice treated at progres-
sively later ages failed to normalize lifespan despite im-
provements in behavior and/or pathology [61].
Disorders driven by loss-of-function in a single cell-
autonomous factor provide an additional challenge for
gene therapy, because the therapy is only effective if the
virus reaches cells specifically deficient in a given gene
product. Spinal Muscular Atrophy Type 1 (SMA1, OMIM
# 25330) results from the loss of cell-autonomous SMN1
and subsequent motor neuron loss. Intravenous adminis-
tration of AAV9 expressing SMN1 targeted sufficient
numbers of neurons across the CNS and was able to suc-
cessfully rescue the SMA1 phenotype after neonatal ad-
ministration in an SMA1 mouse model [62]. Notably, as
for MPS3A, treatment at later ages was not effective. Re-
cently, intravenous treatment with an AAV9 vector in an
ongoing clinical trial for SMA1 demonstrated dramatic
improvements in motor development and survival [63].
It is important to note that the nature of a disease does
not always demand a treatment modality with broad
coverage of the entire CNS. For example, a current gene
therapy strategy for late-onset Parkinson disease (PD,
OMIM # 168600) uses administration of L-DOPA, which
is converted to dopamine by the enzyme Aromatic
L-Amino Acid Decarboxylase (AADC). In PD, the
progressive loss of dopaminergic neurons in the substantia
nigra results in decreased levels of AADC and a corre-
sponding decrease in L-DOPA efficacy. Direct injection of
AAV2 expressing AADC into the putamen led to signifi-
cantly increased motor performance in patients with PD
receiving L-DOPA for the first year post-treatment [64].
However, not all disorders can be successfully treated with
Table 1 Known cellular receptors for different AAV serotypes
Serotype Glycan recognitiona Coreceptor
AAV1 Neu5Acα2-3GalNAcβ1-4GlcNAc Unknown
AAV2 6-O- and N-sulfated heparin Fibroblast [108]/hepatocyte [109] growth factor receptor;
laminin receptor [110]; integrin αVβ5 [111] and α5β1 [112]
AAV3 2-O- and N-sulfated heparin Hepatocyte growth factor receptor [113]; Laminin receptor [110]
AAV4 Galβ1-4GlcNAcβ1-2Manα1-6Manβ1-4GlcNAcβ1-4GlcNAc Unknown
AAV5 Neu5Acα2-3(6S)Galβ1-4GlcNAc Platelet-derived growth factor receptor [114]
AAV6 Neu5Acα2-3GalNAcβ1-4GlcNAc; N-sulfated heparin Epidermal growth factor receptor [115]
AAV7 Unknown Unknown
AAV8 Unknown Laminin receptor [110]
AAV9 Galactose [116] Laminin receptor [110]
aAll glycan recognitions listed, except for AAV9, are from a study by Mietzsch et al. [117] and are more specific glycans compared to the original publications
identifying the primary glycans recognized by each serotype
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direct injection. Indeed, translation of intracranial AAV2
therapies has failed to yield substantial improvements in
both Canavan disease (OMIM # 271900), which results
from a deficiency in non-cell-autonomous enzyme as-
partoacylase, and late-infantile neuronal lipofuscinosis
(OMIM # 204500), which results from loss of the non-
cell-autonomous enzyme tripeptidyl-peptidase-1 [65, 66].
While identifying a definitive cause for the lack of dra-
matic improvements in these trials represents a Sisyphean
task, it seems likely that a lack of sufficient vector spread,
due to the use of AAV2 and an intracranial injection, is at
least partially responsible.
Disorders in which gene dosage must be precisely
maintained present even greater complications for the
development of a successful AAV gene therapy strategy,
as is the case for Rett syndrome (RTT, OMIM #
312750). RTT is an X-linked disorder resulting from
mutations in the MECP2 gene, and the mosaic nature of
MECP2 expression from the mutated X chromosome re-
sults in a cell population with variable cell-autonomous
MECP2 expression. While the loss of MECP2 is associ-
ated with RTT, overexpression of MECP2 can also cause
cell death and an RTT-like syndrome [67]. Thus, AAV
gene therapy for RTT must broadly target cells but must
only permit moderated MECP2 expression in targeted
cells. A recent study led to the development of a vector
containing the MECP2 expression cassette with both a
modified endogenous MECP2 promoter to limit tran-
scription and a 3′ UTR with binding sites for micro-
RNAs known to regulate MECP2 expression. This novel
vector led to enhanced therapeutic efficacy with reduced
liver toxicity relative to previous vectors [68, 69]. On-
going efforts are presently focused on tightening MECP2
expression control and specifically targeting the most
critical cell types.
Disorders in which a multiplicity of genes drives the
underlying pathophysiology can also pose a significant
challenge for the development gene therapy strategies.
Several genes have been linked to the onset of amyo-
trophic lateral sclerosis (ALS, OMIM # 105400), including
SOD1, C9ORF72, TARDBP, and FUS, though roughly 80%
of cases are of unknown etiology [70]. Further, the mo-
lecular mechanisms underlying neuronal death are un-
known, although studies have suggested that oxidative
stress, deficient neurotrophic factor availability, and
chronic inflammation are critical factors. Some studies
have focused on treating the toxic gain-of-function in
SOD1-associated ALS, an approach that led to delayed
onset and lifespan extension [71, 72]. However, therapies
directed at this single factor would treat only 2% of all
ALS patients [73]. Other studies have focused on AAV de-
livery of neurotrophic factors that might confer neuropro-
tection to motoneurons and delay disease onset and
progression [74], though whether such therapies will
translate to humans remains unclear. ALS thus further
highlights the need for a comprehensive understanding of
the molecular underpinnings of a disease to adapt AAV
gene therapy when the appropriate gene(s) for delivery are
not clear.
Special considerations for successful AAV-mediated gene
therapies
Achieving proper gene dosage and expression of multiple
genes
The precise genetic mechanisms underlying some disor-
ders can create unique obstacles in developing optimal
gene therapy approaches for presently untreatable condi-
tions. As highlighted above for RTT, certain gene prod-
ucts are toxic if overexpressed, and so great care must
be taken to tightly control therapeutic gene expression
in this disease. Control of expression levels can occur
across several layers, such as by limiting expression to
specific tissues through injection route and by selecting
capsids with finely tuned specificities. In the absence of
a capsid with the appropriate specificity, cell type-
specific promoters may be carefully selected to achieve
the appropriate level of transcriptional specificity [75].
Additionally, post-transcriptional controls may need to
be engineered into the vector to further tune gene ex-
pression, including regulatory sequences in untranslated
regions or codon selection to limit translation efficiency.
Based on GENCODE 28, > 95% of the 97,713 human
coding sequences (CDSs) are under 3.4 kb (Fig. 1a).
With a strong ubiquitous promoter, single-stranded
rAAV (ssAAV) has sufficient packaging capacity to cover
those 92,827 CDSs. The use of self-complementary
rAAV (scAAV), which significantly increases transduc-
tion efficiency [76], reduces the packaging size to
roughly 2.1 kb, permitting coverage of 66% of human
CDSs (Fig. 1b). To increase the CDS coverage, often at
the cost of promoter strength, different promoters and
polyA sequences can be used (Fig. 1b) [75]. However,
there still remain disorders in which the gene to be de-
livered is simply too large for packaging in a single AAV
virion. To overcome this limitation, research has focused
on packaging the gene of interest across multiple rAAV
virions (recently reviewed in [77]). However, this ap-
proach requires that a single cell will uptake all the ne-
cessary virions—far from a certainty with in vivo
administration. Disorders where multiple genes are be-
lieved to be responsible (e.g., ALS) represent a similar
challenge as packaging multiple genes within the same
virion may not be possible due to size constraints. Fur-
ther, each gene may additionally require distinct regula-
tion to reach critical expression thresholds and/or avoid
toxicity. Again, while multiple constructs can be admin-
istered simultaneously, there is no guarantee that a sin-
gle cell will uptake all the required therapeutic genes.
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Implicit in the situations described above is the need
to achieve an efficient delivery method to the appropri-
ate tissues and cells. Capsid specificity only controls
binding to a cell, which necessarily occurs with variable
efficiency. AAV must also enter the cell and successfully
deliver its therapeutic payload to the nucleus, where the
DNA persists outside of the genome, as recombinant
AAV is non-integrating. The capsid also controls cell
entry and subcellular localization. Thus, generation of
highly efficient vectors with appropriate specificity will
thus require stringent in vivo screening and selection
processes and careful bio-distribution analyses to ensure
that the components necessary to permit and enhance
entry and trafficking are not lost in directed evolution
and rational design approaches.
Coping with immune responses
Even a highly efficient and specific vector delivering an
ideal transgene means nothing if an immune response pre-
vents AAV from reaching the appropriate cells or, worse,
actively destroys cells that receive the therapeutic construct.
It is therefore critical when translating AAV9-mediated
gene therapy for clinical applications to first determine
whether the patient has pre-existing immunity to AAV and
to then mitigate the development of potentially damaging
immune responses to therapy, particularly when the gene
therapy is to be delivered intravenously. While AAV is not
presently thought to cause human disease, little effort was
initially focused in early pre-clinical studies on the ability of
AAV to drive both innate and adaptive immune responses.
However, following the observation of an obvious immune
response to AAV-based gene therapies during clinical trials
[78], studies have begun to evaluate the immune response
to AAV-mediated gene therapy in both pre-clinical models
[18, 79, 80] and human patients [78, 81].
A pre-existing barrier to AAV-based gene therapy stems
from the natural exposure humans receive to AAV, resulting
in pre-existing humoral and cellular immunity [20, 82, 83].
Humoral immune responses, derived from antibody-
producing B cells, can develop against AAV. At least
some anti-AAV antibodies are neutralizing, preventing
AAV from infecting cells, and the presence of pre-
Fig. 1 Packaging capacity of AAV. a Plot of CDS size in bases versus percentile as determined via analysis of all human CDSs in GENCODE 28. b
Top panel: cartoons of single-stranded (ss) and self-complementary (sc) AAV with indicated packaging capacities. Bottom panel: calculations of
gene of interest size as well as percent of transcriptome covered and number of CDSs not covered at the indicated capacities. The gene/promoter
combinations for a relatively strong promoter (CBh) [118] and relatively weak promoter (JeT) [119, 120] are provided as examples to demonstrate
relevant gene packaging possibilities
Lykken et al. Journal of Neurodevelopmental Disorders  (2018) 10:16 Page 5 of 10
existing neutralizing antibodies (NAbs) at even low ti-
ters (e.g., 1:4) in the serum is sufficient to impede
therapeutic efficacy following administration directly
into the bloodstream [19, 84]. The low titers required for
neutralization raises the prospect of neutralization for
therapy delivered directly into the cerebrospinal fluid
(CSF) [85]. IgG is the second most abundant protein in
the CSF after albumin, (7–12% of total protein) [86]; how-
ever, IgG levels in the CSF are 20–1200 times lower than
in the serum for healthy children (< 16 years of age) [87]
and roughly 300 times lower than in the serum for healthy
adults [88]. Thus, pre-existing NAb titers in the serum
would need to be reasonably high to expect a clinically
meaningful neutralizing response in the CSF, which likely
explains why pre-existing NAbs did not inhibit intrathecal
therapy in non-human primates [18]. Further, only around
14% of the healthy adult population shows serum antibody
recognizing AAV9 above a 1:200 titer [20]. Within the
pediatric population (< 18 years of age), the likelihood of
high serum NAb titer is even lower, with only around 35%
of pediatric samples showing a NAb titer against AAV2
above 1:20 [89], for comparison that goes up to around
90% in healthy adults [20]. Thus, pre-existing NAbs can
largely be avoided for first-time gene therapy within the
CNS when using direct injection into the brain or spinal
cord. In contrast, successful intravenous gene therapy ad-
ministration will require NAbs to be removed from the
serum. However, elimination of NAbs from the serum is
not trivial, as it is extraordinarily difficult to eliminate
their source, long-lived plasma cells (LLPCs). LLPCs are
highly resistant to currently available treatments, includ-
ing steroids [90] and irradiation [91, 92]. Indeed, elimin-
ation of LLPCs has been achieved only through complete
immunoablation with antithymocyte globulin [93–95], a
treatment that presents substantial risks for patients. The
co-injection of empty capsids to act as decoys for NAb
binding has also been proposed to circumvent pre-
existing NAbs [96]. However, initial pre-clinical studies
demonstrated that roughly tenfold higher doses of empty
capsid must be used to overcome relatively low (1:1) NAb
titers, and even greater relative doses are required to over-
come higher NAb titers [96]. Thus, empty capsid adminis-
tration as an approach to prevent NAb interference is
severely limited by the ability to reliably produce sufficient
amounts of empty capsid. Further, inclusion of empty cap-
sids only further increases the antigenic load. Ultimately,
circumventing pre-existing NAbs to AAV will likely re-
quire the development of safe treatments that specifically
target LLPCs, though these treatments will then require
patients to be vaccinated again post-therapy to reduce vul-
nerability to common infections.
In addition to extant humoral immunity, pre-existing
cellular immunity, particularly that derived from cyto-
toxic CD8+ T cells, represents a threat to successful gene
therapy. Indeed, while understandably little work has
evaluated T cell responses within the CNS post-therapy,
CD8+ T cell responses have been observed to limit
therapeutic efficacy in gene therapy clinical trials for
hemophilia [78, 97]. Pre-existing CD8+ T cell immunity
poses a greater risk to the patient beyond interfering
with therapy, however, as the cytotoxic response can
cause significant tissue damage. Activated CD8+ T cells
release a host of inflammatory mediators to promote
immune responses (e.g., CCL3, TNF-α, and INF-γ) as well
as cytotoxic molecules enabling direct cell killing (e.g.,
perforin and granzyme B). Further, T cells are able to es-
tablish a local memory pool within the CNS [98, 99]. As
for humoral immunity, the rate of pre-existing CD8+ T
cell immunity to AAV within splenocytes is rather high: ~
70% in patients 5 years of age and older and ~ 16% in
patients under 5 years of age [100]. Further, these pre-
existing memory cells are less frequent in the blood than
spleen [101] and require multiple rounds of stimulation to
observe [100, 101]. These observations highlight the need
for detailed study of anti-AAV T cell responses and sug-
gest that pre-existing anti-AAV CD8+ T cells are quite
likely present in patients. Fortunately, decades of research
into transplant rejection and autoimmune diseases have
yielded treatments that are able to significantly dampen
cellular immune responses, although such treatments may
not always be effective prophylactics [102]. Indeed, in
some cases, immunsuppressive regimens have led to
increases in circulating effector and central memory anti-
AAV CD8+ T cells [102]. How these therapies may impact
long-term immunity requires careful consideration, as
long-term immunosuppression poses tremendous and
protracted risks, particularly in infants and children. Thor-
ough screening of pre-existing T cell responses (e.g., via
multi-parameter flow cytometry) can determine the na-
ture of pre-existing cellular immune responses and permit
selection of the most appropriate immunosuppressive
regimen, although it remains to be determined whether
the screening of T cells in the blood will accurately de-
scribe the breadth of pre-existing cellular immunity in a
given patient.
Overcoming pre-existing immunity is not trivial, but
careful selection of administration routes and immuno-
suppression regimens following patient screening can go
a long way to enable treatment. Once introduced, gene
therapy will also induce immune responses to the vector
[66, 81, 103, 104] and possibly to the therapeutic trans-
gene. While immune responses to AAV are problematic
and may stymie potential re-dosing efforts, responses to
the therapeutic transgene pose a much greater risk for pa-
tients. Indeed, anti-transgene responses inhibit enzyme re-
placement therapies in pre-clinical models [105, 106] and
may reduce efficacy in humans [107]. While natural fea-
tures of the therapeutic transgene (e.g., expression level,
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natural localization of the gene, etc.) will partially deter-
mine the overall risk of an immune response to the trans-
gene, efforts to minimize this risk will enhance overall
patient safety and therapeutic efficacy. The administration
route can control the magnitude and timing of an im-
mune response, with direct treatment of the CNS redu-
cing the risk of severe, systemic immune responses.
Constructing selective and efficient vectors to reduce re-
quired viral load can also limit the magnitude of immune
responses by minimizing inflammation. Immunosuppres-
sive drug regimens can also impede immune activation, al-
though these drugs typically have unintended long-term
consequences in infants and children. However, immuno-
suppression represents a viable option until methods are
devised to permit long-term tolerance to the therapeutic
transgene while maintaining immunocompetence.
Conclusions
The progression towards meaningful therapies for neu-
rodevelopmental disorders has greatly accelerated over
the past few years. CNS-directed AAV gene therapies,
particularly therapies using AAV9, are producing prom-
ising pre-clinical results, especially when provided early
in the course of disease, and are increasingly translating
from the bench into phase I clinical trials. Increasing re-
search to understand the underlying biology of neurode-
velopmental disorders will help tremendously to define
the relevant cell types and treatment paradigms. When
coupled with continued improvements in construct de-
sign and the creation of novel AAV variants with specific
and enhanced targeting capabilities, there is much hope
for the treatment of even complex disorders. As treat-
ments transition into clinical practice, efforts to prevent
inhibitory immune responses will be a critical area of
focus. Working to understand anti-therapy immunity on
the pre-clinical side and careful monitoring during clin-
ical trials will no doubt provide a wealth of insight and
help focus the development of safe and highly efficacious
therapies.
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